Dr Elgebaly’s expertise is in cardiovascular complications of diabetes mellitus in stroke. He earned his PhD from the University of Georgia Athens (UGA) from the program of Clinical and Experimental Therapeutics using a translational approach in his work. His area is biomarkers of neurovascular injury such understanding “Matrix Metalloproteinase -9 (MMP-9) Kinetic profile in diabetes and hyperglycemia and its role in worsening hemorrhagic stroke”. Dr Elgebaly proposes the use of multiplex assays and ELISAs to measure changes in MMP-9 expression and activity in mammalian-cultured cells exposed to hypoxic and hyperglycemic conditions. In addition, since he is interested in studying temporary focal ischemia which causes greater hemorrhagic transformation in diabetes secondary to increased cerebrovascular matrix metalloprotease (MMP) activity and tortuosity. This diabetes-induced cerebrovascular remodeling is MMP dependent. Prevention of vascular remodeling by glucose control or MMP inhibition reduces hemorrhagic transformation in diabetic stroke is a goal of his research. Vascular remodeling markers including MMP-9 activity in diabetes are the major focus of his studies.